Immunogen (IMGN) Misses Q2 EPS by 3c

Immunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $14.2 million versus the consensus estimate of $16.18 million.

GUIDANCE:

Immunogen sees FY2022 revenue of $75-85 million, versus the consensus of $84.7 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Gentex Corporation (GNTX) Tops Q2 EPS by 8c ; Offers Guidance
• TPU-As-A-Service could boost Google’s 2028 profit by over 15%: Barclays
• HSBC starts SpaceX at Hold, sees execution risks tempering long-term AI ambitions